RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > It’s the Law: The European Commission’s Report on the Inquiry Into the Pharmaceutical Sector: A Cri

It’s the Law: The European Commission’s Report on the Inquiry Into the Pharmaceutical Sector: A Critical Analysis From a Patent and Antitrust Law Perspective

Posted 01 January 2010

On 8 July 2009, the European Commission published its final report on its inquiry into the pharmaceutical sector.1 The report concluded that competition is not functioning properly in the pharmaceutical sector. According to the findings of the Commission, the entry of generic drugs onto the European market is being delayed and fewer new pharmaceutical products have entered the market in recent years. "When it comes to generic entry, every week and month of delay costs money to patients and taxpayers. We will not hesitate to apply the antitrust rules where such delays result from anticompetitive practices. The first antitrust investigations are already underway, and regulatory adjustments are expected to follow dealing with a range of problems in the sector," Commissioner for Competition Neelie Kroes commented.2

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe